Echte Hilfe für Betroffene oder medialer Hype – was können wir von den neuen Medikamenten zur Behandlung der Alzheimer-Erkrankung wirklich erwarten? Weltweit führen Fachexperten kontroverse Diskussionen über die sogenannten monoklonalen Antikörper, die für die Behandlung von leichten kognitiven Beeinträchtigungen und Alzheimer-Demenz vorgesehen sind. Mit den Fakten aus der Forschung werden …
Gender Studies in medicine is a highly relevant societal topic. This is because gender plays an important role in both the development and treatment of diseases. Gender-specific differences are also evident in dementia patients. For example, women develop dementia more often than men and show a different...
Die sogenannte Amyloid-Hypothese hat die Alzheimerforschung über Jahrzehnte hinweg maßgeblich geprägt und zur Entwicklung der ersten Antikörpertherapien geführt. Trotz dieser Fortschritte bleiben die klinischen Erfolge begrenzt, was zunehmend Fragen zur Wirksamkeit und zum tatsächlichen Nutzen dieser Therapien aufwirft. In unserem Webinar hat Prof. Dr. Christian Behl, einer der international renommiertesten …
The risk of developing Alzheimer's dementia is higher for people with mild cognitive impairment (MCI). But to what extent is it possible to predict the progression to Alzheimer's dementia at all? Why can this be an important factor? An accurate prediction could help doctors in their decision-making regarding treatment of...
Echte Hilfe für Betroffene oder medialer Hype – was können wir von den neuen Medikamenten zur Behandlung der Alzheimer-Erkrankung wirklich erwarten? Weltweit führen Fachexperten kontroverse Diskussionen über die sogenannten monoklonalen Antikörper, die für die Behandlung von leichten kognitiven Beeinträchtigungen und Alzheimer-Demenz vorgesehen sind. Mit den Fakten aus der Forschung werden …
In the fourth edition of our new special newsletter SCHLAGLICHT – New Drugs for Dementia, Florian Weidinger, research associate at digiDEM Bayern, deals with the publication "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint" by the research team led by Professor Linus Jönsson from the Karolinska Institutet in Sweden. In the journal The Lancet…
In the third issue of our new special newsletter "SCHLAGLICHT – New Medications for Dementia," Dr. Nikolas Dietzel, a research associate at digiDEM Bayern, discusses the publication by scientists from Europe, the USA, and Australia, led by Professor Poul F. Høilund-Carlsen from Odense University Hospital in Denmark. In the article titled "Donanemab, another anti-Alzheimer’s…"
Researchers from Ireland and Sweden have discovered that women who suffer from pregnancy poisoning appear to have a significantly increased future risk of vascular dementia. If dementia develops later in life, it may have been pre-empted in younger years, for example, during pregnancy. It has long been known...
Korean researchers investigated whether there is a connection between migraines and dementia. After analyzing data from more than 11,000 dementia patients and over 45,700 control subjects, they found that women with a history of migraines have an increased risk of dementia. Generally, there is increasing evidence that women and men experience different...
Certain neuropsychiatric symptoms, such as depression and psychosis, occur more frequently in women with Alzheimer's dementia than in men with Alzheimer's dementia. This is one of the central findings of a study by researchers from the Netherlands, Sweden, the USA, Canada, and Australia. In people with Alzheimer's dementia (AD), neuropsychiatric...
